Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis.

American journal of cardiovascular disease

Moura LM, Faria S, Brito M, Pinto FJ, Kristensen SD, Barros IM, Rajamannan N, Rocha-Gonçalves F.
PMID: 22720202
Am J Cardiovasc Dis. 2012;2(2):123-32. Epub 2012 May 15.

INTRODUCTION AND OBJECTIVES: Paraoxonases may exert anti-atherogenic action by reducing lipid peroxidation. Previous studies examined associations between polymorphisms in the paraoxonase 1 (PON1) gene and development of coronary artery disease (CAD), with inconsistent results. Given the similarities in clinical...

Cite
Moura LM, Faria S, Brito M, et al. Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. Am J Cardiovasc Dis. 2012;2(2):123-32
Moura, L. M., Faria, S., Brito, M., Pinto, F. J., Kristensen, S. D., Barros, I. M., Rajamannan, N., & Rocha-Gonçalves, F. (2012). Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. American journal of cardiovascular disease, 2(2), 123-32.
Moura, Luis M, et al. "Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis." American journal of cardiovascular disease vol. 2,2 (2012): 123-32.
Moura LM, Faria S, Brito M, Pinto FJ, Kristensen SD, Barros IM, Rajamannan N, Rocha-Gonçalves F. Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. Am J Cardiovasc Dis. 2012;2(2):123-32. Epub 2012 May 15. PMID: 22720202; PMCID: PMC3371627.
Copy Download .nbib Format: NLM
Drug-drug interactions in hospitalized cardiac patients.

Journal of young pharmacists : JYP

Mateti U, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy S, Ramachandran P.
PMID: 22224041
J Young Pharm. 2011 Oct;3(4):329-33. doi: 10.4103/0975-1483.90246.

Drug-drug interactions (DDIs) are defined as two or more drugs interacting in such a manner that the effectiveness or toxicity of one or more drugs is altered. DDI in patients receiving multidrug therapy is a major concern. The aim...

Cite
Mateti U, Rajakannan T, Nekkanti H, et al. Drug-drug interactions in hospitalized cardiac patients. J Young Pharm. 2011;3(4):329-33doi: 10.4103/0975-1483.90246.
Mateti, U., Rajakannan, T., Nekkanti, H., Rajesh, V., Mallaysamy, S., & Ramachandran, P. (2011). Drug-drug interactions in hospitalized cardiac patients. Journal of young pharmacists : JYP, 3(4), 329-33. https://doi.org/10.4103/0975-1483.90246
Mateti, Uv, et al. "Drug-drug interactions in hospitalized cardiac patients." Journal of young pharmacists : JYP vol. 3,4 (2011): 329-33. doi: https://doi.org/10.4103/0975-1483.90246
Mateti U, Rajakannan T, Nekkanti H, Rajesh V, Mallaysamy S, Ramachandran P. Drug-drug interactions in hospitalized cardiac patients. J Young Pharm. 2011 Oct;3(4):329-33. doi: 10.4103/0975-1483.90246. PMID: 22224041; PMCID: PMC3249747.
Copy Download .nbib Format: NLM
Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications.

JAMA internal medicine

Fain KM, Rajakannan T, Tse T, Williams RJ, Zarin DA.
PMID: 29532058
JAMA Intern Med. 2018 Jul 01;178(7):990-992. doi: 10.1001/jamainternmed.2018.0263.

No abstract available.

Cite
Fain KM, Rajakannan T, Tse T, et al. Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications. JAMA Intern Med. 2018;178(7):990-992doi: 10.1001/jamainternmed.2018.0263.
Fain, K. M., Rajakannan, T., Tse, T., Williams, R. J., & Zarin, D. A. (2018). Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications. JAMA internal medicine, 178(7), 990-992. https://doi.org/10.1001/jamainternmed.2018.0263
Fain, Kevin M, et al. "Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications." JAMA internal medicine vol. 178,7 (2018): 990-992. doi: https://doi.org/10.1001/jamainternmed.2018.0263
Fain KM, Rajakannan T, Tse T, Williams RJ, Zarin DA. Results Reporting for Trials With the Same Sponsor, Drug, and Condition in ClinicalTrials.gov and Peer-Reviewed Publications. JAMA Intern Med. 2018 Jul 01;178(7):990-992. doi: 10.1001/jamainternmed.2018.0263. PMID: 29532058; PMCID: PMC5885263.
Copy Download .nbib Format: NLM
4-Amino-pyridinium 4-carb-oxy-butano-ate.

Acta crystallographica. Section E, Structure reports online

Fun HK, Hemamalini M, Rajakannan V.
PMID: 21588399
Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 24;66:o2108. doi: 10.1107/S1600536810028734.

The asymmetric unit of the title salt, C(5)H(7)N(2) (+)·C(5)H(7)O(4) (-), contains two 4-amino-pyridinium cations and two 4-carb-oxy-butano-ate anions. Each 4-amino-pyridinium cation is planar, with a maximum deviation of 0.005 (2) Å. Both 4-carb-oxy-butano-ate anions adopt an extended conformation. In...

Cite
Fun HK, Hemamalini M, Rajakannan V. 4-Amino-pyridinium 4-carb-oxy-butano-ate. Acta Crystallogr Sect E Struct Rep Online. 2010;66:o2108doi: 10.1107/S1600536810028734.
Fun, H. K., Hemamalini, M., & Rajakannan, V. (2010). 4-Amino-pyridinium 4-carb-oxy-butano-ate. Acta crystallographica. Section E, Structure reports online, 66o2108. https://doi.org/10.1107/S1600536810028734
Fun, Hoong-Kun, et al. "4-Amino-pyridinium 4-carb-oxy-butano-ate." Acta crystallographica. Section E, Structure reports online vol. 66 (2010): o2108. doi: https://doi.org/10.1107/S1600536810028734
Fun HK, Hemamalini M, Rajakannan V. 4-Amino-pyridinium 4-carb-oxy-butano-ate. Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 24;66:o2108. doi: 10.1107/S1600536810028734. PMID: 21588399; PMCID: PMC3007404.
Copy Download .nbib Format: NLM
Slowing the progression of aortic stenosis.

Current treatment options in cardiovascular medicine

Maganti K, Rajamannan N.
PMID: 18325304
Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):18-26. doi: 10.1007/s11936-008-0003-3.

Aortic stenosis (AS) is the most frequent valvular heart disease in the Western world. The only definitive treatment for this disorder is surgical replacement of the aortic valve. Recent histopathologic studies have provided important insights into the pathogenesis of...

Cite
Maganti K, Rajamannan N. Slowing the progression of aortic stenosis. Curr Treat Options Cardiovasc Med. 2008;10(1):18-26doi: 10.1007/s11936-008-0003-3.
Maganti, K., & Rajamannan, N. (2008). Slowing the progression of aortic stenosis. Current treatment options in cardiovascular medicine, 10(1), 18-26. https://doi.org/10.1007/s11936-008-0003-3
Maganti, Kameswari, and Rajamannan, Nalini. "Slowing the progression of aortic stenosis." Current treatment options in cardiovascular medicine vol. 10,1 (2008): 18-26. doi: https://doi.org/10.1007/s11936-008-0003-3
Maganti K, Rajamannan N. Slowing the progression of aortic stenosis. Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):18-26. doi: 10.1007/s11936-008-0003-3. PMID: 18325304.
Copy Download .nbib Format: NLM
2-Amino-5-chloro-pyrimidin-1-ium hydrogen maleate.

Acta crystallographica. Section E, Structure reports online

Fun HK, Hemamalini M, Rajakannan V.
PMID: 22259394
Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68:o108. doi: 10.1107/S1600536811051646. Epub 2011 Dec 14.

In the title salt, C(4)H(5)ClN(3) (+)·C(4)H(3)O(4) (-), the 2-amino-5-chloro-pyrimidinium cation is protonated at one of its pyrimidine N atoms. In the roughly planar (r.m.s. deviation = 0.026 Å) hydrogen malate anion, an intra-molecular O-H⋯O hydrogen bond generates an S(7)...

Cite
Fun HK, Hemamalini M, Rajakannan V. 2-Amino-5-chloro-pyrimidin-1-ium hydrogen maleate. Acta Crystallogr Sect E Struct Rep Online. 2011;68:o108doi: 10.1107/S1600536811051646.
Fun, H. K., Hemamalini, M., & Rajakannan, V. (2012). 2-Amino-5-chloro-pyrimidin-1-ium hydrogen maleate. Acta crystallographica. Section E, Structure reports online, 68o108. https://doi.org/10.1107/S1600536811051646
Fun, Hoong-Kun, et al. "2-Amino-5-chloro-pyrimidin-1-ium hydrogen maleate." Acta crystallographica. Section E, Structure reports online vol. 68 (2012): o108. doi: https://doi.org/10.1107/S1600536811051646
Fun HK, Hemamalini M, Rajakannan V. 2-Amino-5-chloro-pyrimidin-1-ium hydrogen maleate. Acta Crystallogr Sect E Struct Rep Online. 2012 Jan;68:o108. doi: 10.1107/S1600536811051646. Epub 2011 Dec 14. PMID: 22259394; PMCID: PMC3254455.
Copy Download .nbib Format: NLM
Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital.

Drug, healthcare and patient safety

Thiyagu R, Mallayasamy SR, Rajesh V, Muralidhar V, Smitha P, Sudha V, Laxminarayana BK.
PMID: 21701622
Drug Healthc Patient Saf. 2010;2:95-100. doi: 10.2147/dhps.s11222. Epub 2010 Jun 30.

OBJECTIVE: Adverse drug events (ADEs) are drug-related events which continue to pose serious challenges to the safety of patients. There are a number of ways to monitor ADEs, and the use of indictors to screen them provides an alternative...

Cite
Thiyagu R, Mallayasamy SR, Rajesh V, et al. Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital. Drug Healthc Patient Saf. 2010;2:95-100doi: 10.2147/dhps.s11222.
Thiyagu, R., Mallayasamy, S. R., Rajesh, V., Muralidhar, V., Smitha, P., Sudha, V., & Laxminarayana, B. K. (2010). Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital. Drug, healthcare and patient safety, 295-100. https://doi.org/10.2147/dhps.s11222
Thiyagu, Rajakannan, et al. "Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital." Drug, healthcare and patient safety vol. 2 (2010): 95-100. doi: https://doi.org/10.2147/dhps.s11222
Thiyagu R, Mallayasamy SR, Rajesh V, Muralidhar V, Smitha P, Sudha V, Laxminarayana BK. Development of indicators for identifying adverse drug events in an Indian tertiary care teaching hospital. Drug Healthc Patient Saf. 2010;2:95-100. doi: 10.2147/dhps.s11222. Epub 2010 Jun 30. PMID: 21701622; PMCID: PMC3108708.
Copy Download .nbib Format: NLM
4-Amino-pyridinium 2-hy-droxy-benzoate.

Acta crystallographica. Section E, Structure reports online

Fun HK, Hemamalini M, Rajakannan V.
PMID: 21588323
Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 14;66:o2010-1. doi: 10.1107/S1600536810027042.

In the salicylate anion of the title salt, C(5)H(7)N(2) (+)·C(7)H(5)O(3) (-), an intra-molecular O-H⋯O hydrogen bond generating an S(6) ring motif is observed. In the crystal structure, the cations and anions are linked into a two-dimensional network parallel to...

Cite
Fun HK, Hemamalini M, Rajakannan V. 4-Amino-pyridinium 2-hy-droxy-benzoate. Acta Crystallogr Sect E Struct Rep Online. 2010;66:o2010-1doi: 10.1107/S1600536810027042.
Fun, H. K., Hemamalini, M., & Rajakannan, V. (2010). 4-Amino-pyridinium 2-hy-droxy-benzoate. Acta crystallographica. Section E, Structure reports online, 66o2010-1. https://doi.org/10.1107/S1600536810027042
Fun, Hoong-Kun, et al. "4-Amino-pyridinium 2-hy-droxy-benzoate." Acta crystallographica. Section E, Structure reports online vol. 66 (2010): o2010-1. doi: https://doi.org/10.1107/S1600536810027042
Fun HK, Hemamalini M, Rajakannan V. 4-Amino-pyridinium 2-hy-droxy-benzoate. Acta Crystallogr Sect E Struct Rep Online. 2010 Jul 14;66:o2010-1. doi: 10.1107/S1600536810027042. PMID: 21588323; PMCID: PMC3007529.
Copy Download .nbib Format: NLM
Crystal structure of 3-amino-1-propyl-pyridinium bromide.

Acta crystallographica. Section E, Structure reports online

Venkatesan P, Rajakannan V, Thamotharan S.
PMID: 25552997
Acta Crystallogr Sect E Struct Rep Online. 2014 Nov 29;70:580-3. doi: 10.1107/S1600536814025665. eCollection 2014 Dec 01.

The title mol-ecular salt, C8H13N2 (+)·Br(-), crystallizes with two independent 3-amino-pyridinium cations and two bromide anions in the asymmetric unit (Z' = 2). In the pyridine ring, the N atom is alkyl-ated by a propyl group. The dihedral angle...

Cite
Venkatesan P, Rajakannan V, Thamotharan S. Crystal structure of 3-amino-1-propyl-pyridinium bromide. Acta Crystallogr Sect E Struct Rep Online. 2014;70:580-3doi: 10.1107/S1600536814025665.
Venkatesan, P., Rajakannan, V., & Thamotharan, S. (2014). Crystal structure of 3-amino-1-propyl-pyridinium bromide. Acta crystallographica. Section E, Structure reports online, 70580-3. https://doi.org/10.1107/S1600536814025665
Venkatesan, P, et al. "Crystal structure of 3-amino-1-propyl-pyridinium bromide." Acta crystallographica. Section E, Structure reports online vol. 70 (2014): 580-3. doi: https://doi.org/10.1107/S1600536814025665
Venkatesan P, Rajakannan V, Thamotharan S. Crystal structure of 3-amino-1-propyl-pyridinium bromide. Acta Crystallogr Sect E Struct Rep Online. 2014 Nov 29;70:580-3. doi: 10.1107/S1600536814025665. eCollection 2014 Dec 01. PMID: 25552997; PMCID: PMC4257424.
Copy Download .nbib Format: NLM
Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime.

Journal of pharmacology & pharmacotherapeutics

Prabhu VA, Doddapaneni S, Thunga G, Thiyagu R, Prabhu MM, Naha K.
PMID: 24250210
J Pharmacol Pharmacother. 2013 Oct;4(4):291-3. doi: 10.4103/0976-500X.119719.

Steven Johnson syndrome (SJS) is a rare drug induced mucocutaneous reaction. Here, we present an elaborate report of a 28-year-old female patient who developed Phenytoin induced SJS, which was exacerbated by cefepime.

Cite
Prabhu VA, Doddapaneni S, Thunga G, et al. Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime. J Pharmacol Pharmacother. 2013;4(4):291-3doi: 10.4103/0976-500X.119719.
Prabhu, V. A., Doddapaneni, S., Thunga, G., Thiyagu, R., Prabhu, M. M., & Naha, K. (2013). Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime. Journal of pharmacology & pharmacotherapeutics, 4(4), 291-3. https://doi.org/10.4103/0976-500X.119719
Prabhu, Varsha A, et al. "Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime." Journal of pharmacology & pharmacotherapeutics vol. 4,4 (2013): 291-3. doi: https://doi.org/10.4103/0976-500X.119719
Prabhu VA, Doddapaneni S, Thunga G, Thiyagu R, Prabhu MM, Naha K. Phenytoin induced Stevens-Johnson syndrome exacerbated by cefepime. J Pharmacol Pharmacother. 2013 Oct;4(4):291-3. doi: 10.4103/0976-500X.119719. PMID: 24250210; PMCID: PMC3826009.
Copy Download .nbib Format: NLM
Insulin chewing gum: Need of the day for diabetic patients.

International journal of pharmaceutical investigation

Mateti UV, Adla N, Rajakannan T, Valakkathala R.
PMID: 23071934
Int J Pharm Investig. 2011 Jul;1(3):131-4. doi: 10.4103/2230-973X.85961.

Chewing gum is an excellent drug delivery system for self medication as it is convenient, can be administered discreetly without water and offers the removal of 'needle fear' for the patients. As it releases insulin orally, it helps in...

Cite
Mateti UV, Adla N, Rajakannan T, et al. Insulin chewing gum: Need of the day for diabetic patients. Int J Pharm Investig. 2011;1(3):131-4doi: 10.4103/2230-973X.85961.
Mateti, U. V., Adla, N., Rajakannan, T., & Valakkathala, R. (2011). Insulin chewing gum: Need of the day for diabetic patients. International journal of pharmaceutical investigation, 1(3), 131-4. https://doi.org/10.4103/2230-973X.85961
Mateti, Uday Venkat, et al. "Insulin chewing gum: Need of the day for diabetic patients." International journal of pharmaceutical investigation vol. 1,3 (2011): 131-4. doi: https://doi.org/10.4103/2230-973X.85961
Mateti UV, Adla N, Rajakannan T, Valakkathala R. Insulin chewing gum: Need of the day for diabetic patients. Int J Pharm Investig. 2011 Jul;1(3):131-4. doi: 10.4103/2230-973X.85961. PMID: 23071934; PMCID: PMC3465133.
Copy Download .nbib Format: NLM
Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital.

North American journal of medical sciences

Mateti UV, Nekkanti H, Vilakkathala R, Rajakannan T, Mallayasamy S, Ramachandran P.
PMID: 22536562
N Am J Med Sci. 2012 Apr;4(4):185-9. doi: 10.4103/1947-2714.94945.

BACKGROUND: Adverse drug reactions (ADRs) occur frequently with cardiovascular drugs leading to change in therapy, increasing morbidity, and mortality.AIM: The study was conducted to evaluate the incidence of ADRs due to angiotensin-converting enzyme Inhibitors in cardiology department.MATERIALS AND METHODS:...

Cite
Mateti UV, Nekkanti H, Vilakkathala R, et al. Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. N Am J Med Sci. 2012;4(4):185-9doi: 10.4103/1947-2714.94945.
Mateti, U. V., Nekkanti, H., Vilakkathala, R., Rajakannan, T., Mallayasamy, S., & Ramachandran, P. (2012). Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. North American journal of medical sciences, 4(4), 185-9. https://doi.org/10.4103/1947-2714.94945
Mateti, Uday Venkat, et al. "Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital." North American journal of medical sciences vol. 4,4 (2012): 185-9. doi: https://doi.org/10.4103/1947-2714.94945
Mateti UV, Nekkanti H, Vilakkathala R, Rajakannan T, Mallayasamy S, Ramachandran P. Pattern of Angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. N Am J Med Sci. 2012 Apr;4(4):185-9. doi: 10.4103/1947-2714.94945. PMID: 22536562; PMCID: PMC3334259.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries